Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal 3.3 Cost-Effectiveness Evidence Submitted by the Company, 14th para, final sentence should be removed. Correction to: PharmacoEconomics (2021) https://doi.org/10.1007/s40273-021-01098-3 The following sentence has been added to the end of the abstract of the original online version "This decision was subsequently appealed, and an appeal decision has been reached.". [Extracted from the article]